You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • FRI0186 Long-term safety and efficacy of 4-weekly certolizumab pegol monotherapy and combination therapy in rheumatoid arthritis: 5-year results from an open-label extension study

Citation Tools

Article menu
Download PDFPDF
Poster Presentation
Rheumatoid arthritis - anti-TNF therapy
FRI0186 Long-term safety and efficacy of 4-weekly certolizumab pegol monotherapy and combination therapy in rheumatoid arthritis: 5-year results from an open-label extension study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Fleischmann R, van Vollenhoven R, Vencovsky J, et al
FRI0186 Long-term safety and efficacy of 4-weekly certolizumab pegol monotherapy and combination therapy in rheumatoid arthritis: 5-year results from an open-label extension study
Annals of the Rheumatic Diseases 2013;72:A435.